Open in interactive viewer → charts, metric popovers & call review

Inovio Got Its Approval. The Stock Sold It, and the Story Moved to the Formulary

VOCERYQ makes Inovio a commercial company after years of burning cash — but the quiet shifts are a smaller confirmatory trial, a vanishing pricing script, and an $80.5 million raise that bought the launch, not the upside
INO · Earnings Call · 2026-11-10

Inovio Got Its Approval. The Stock Sold It, and the Story Moved to the Formulary

For a company that has spent the better part of two decades being a science project, Inovio Pharmaceuticals picked an odd week to become a business. On this call the company confirmed the FDA's accelerated approval of VOCERYQ (formerly INO-3107) for adults with recurrent respiratory papillomatosis — the first FDA-approved plasmid DNA-based immunotherapy and, per Chief Medical Officer Mike Sumner, the first approved electroporation device in the world. The label is broad, the patient population is estimated at 25,000 adults in the U.S., and the prescriber base is roughly 400 laryngologists.

And yet the tape peaked on November 2 at $1.89 and has since given back 22%. The 90-day return is still +21.9%, but that number is doing all its work in a nine-day stretch that ran +91% into the decision. This is the classic shape of an approval that was bought before it happened: $102 million market cap, a stock still down 99.6% from its 2020 peak, and a catalyst fully priced by the time the press release landed.

What management stopped talking about

The most interesting thing in the keyword record is not what surged but what collapsed. For at least four quarters, Inovio's narrative was organized around a regulatory fight: informal meeting requests, an assessment aid submitted in February, arguments about eligibility for the accelerated pathway, and above all a competitive differentiator built on minimal residual disease — the point that VOCERYQ, unlike Precigen's PAPZIMEOS, requires no scoping or surgical debulking during the dosing window. That keyword spiked hard in the first quarter of 2026 and has since fallen off more sharply than almost any other term in the company's vocabulary.

It fell off because it won. On this call the differentiation argument is no longer a regulatory persuasion exercise; it is a sales pitch. Steve Egge, the Chief Commercial Officer, now talks about broad adult indication and a field deployment partner — Syneos Health — rather than about convincing an agency.

Second thing that vanished: price. In May, Jacqui Shea was explicit that “we are thinking of rare disease pricing. Clearly, in our payer research that we've conducted, payers recognize that rare disease pricing is appropriate for this indication.” — Jacqueline Shea, President and Chief Executive Officer · 2026-05-13 In August 2025, Egge put a number on the neighborhood: “the SpringWorks Therapeutics product, Ogsiveo that's priced at $360,000 a year. That's kind of the range of pricing that we're thinking.” — Steven Egge, Chief Commercial Officer · 2025-08-13 On the launch call itself — the one call where price actually matters — it does not come up once, and no analyst asks. That silence is worth noting. Either pricing research is still live, or the company would rather not anchor a number before payer conversations begin.

The confirmatory trial quietly got easier

Buried in Sumner's prepared remarks is a design change that deserves more attention than it got in Q&A. Prior calls described a confirmatory study of roughly 100 patients across about 20 U.S. sites, with a placebo-controlled design and an inclusion bar of two or more prior surgeries. Today's version:

We have agreed with the agency that the study should enroll at least 50 adult and pediatric patients with RRP requiring 3 or more surgical interventions in the 12 months prior to treatment with VOCERYQ... we expect the study to evaluate the number of surgical interventions required over at least 3 years following completion of treatment, and compare this to an appropriate external control group or scientifically justified threshold.

Michael Sumner, Chief Medical Officer · 2026-11-10

Fifty patients instead of a hundred. Pediatric enrollment added. An external control or a "scientifically justified threshold" in place of the placebo arm that was being discussed a year ago. This is the confirmatory trial getting meaningfully cheaper and faster to run — a real de-risking of the post-approval obligation, disclosed in a subordinate clause. Worth remembering that in August the company was still “awaiting the FDA's comments on our submitted protocol to the IND” — Michael Sumner, Chief Medical Officer · 2026-08-12; three months later it has an agreed shape.

The balance sheet bought the launch, not the company

The financials are the part that keeps this from being a clean celebration. Inovio's cash runway stood at barely two quarters as of the last filed quarter, with liabilities at 91% of assets. The fix came in two pieces: a public offering netting roughly $80.5 million, plus $10.9 million of warrant exercises after quarter-end, layered on $48.4 million of cash and short-term investments at September 30.

Peter Kies was precise about what that buys: runway into late Q4 2027, past the launch, explicitly excluding product revenue. Q4 2026 burn is guided to about $21 million as commercialization ramps. And the first revenue is a 2027 event — product available to order roughly 60 days from approval, full field deployment in Q1 2027, revenue "expected to commence in 2027." For a company whose quarterly operating loss is still around $19 million, that is a long bridge funded by shareholders.

The cost discipline is genuine, if brutal. R&D spend is down 80% from the 2022 peak of $67 million a quarter to $11 million, and Q3 operating expenses fell to $19.8 million from $21.2 million a year ago. The reported net loss of $49.2 million is worse than the $45.5 million prior-year figure only because of a $26.9 million non-cash mark on warrant liabilities — a share-price artifact, not a cash event. On a per-share basis the loss actually improved, to $0.50 from $0.87, because the share count roughly doubled.

The launch math, and the second entrant problem

The commercial plan is narrow and specific: about 100 integrated delivery networks and academic institutions hold roughly 80% of RRP patients, community and private practice hold the rest, and 20 territories plus reimbursement specialists are designed to cover about 90% of patient potential. Payer coverage for ~80% of covered lives is expected within nine months, alongside a permanent J-code application and a support program with a single point of contact.

The framing of the competitor has shifted too. Jacqui Shea, asked where VOCERYQ wins, led with validation rather than displacement: “with PAPZIMEOS' strong early uptake, where do you see VOCERYQ positioned to win at the launch?” — Peter Chen, Analyst · 2026-11-10 — and the answer began “what we're seeing with PAPZIMEOS in terms of the strong uptake that they've seen really indicates the high unmet need in this patient population” — Jacqueline Shea, President and Chief Executive Officer · 2026-11-10. A year ago the same question produced a detailed mechanism-of-action argument about neutralizing antibodies to the gorilla adenoviral vector. Now the first mover is evidence of market depth, which is the right answer for a second entrant but a different posture than the one sold in prior quarters.

What remains genuinely unclaimed is the platform. Sumner used the approval as a regulatory and CMC credential — “the fact that we have the first approved electroporation device in the world” — Michael Sumner, Chief Medical Officer · 2026-11-10 — and pointed to nonclinical proof-of-concept for alkaline phosphatase in hypophosphatasia presented at the Soft Bones Conference, plus the longer-running DPROT work in hemophilia A and Fabry disease. That ties into a theme the broader market is already paying for elsewhere: durability of response and World Muscle Society-adjacent rare-disease data has been among the better-performing keyword clusters over the trailing year. The 96-week dMAb expression data without anti-drug antibodies is the asset that a partner would actually pay for, and Shea was frank that partnerships are how those programs advance.

The near-term question is narrower than the science. A $102 million company with a first-in-class approval, an external-control confirmatory study, a payer-access window measured in months, and no revenue until 2027 is a bet on execution velocity in roughly 100 accounts. The approval settled the regulatory argument that dominated four prior calls. It did not settle whether the ~$360,000-a-year pricing script — still unspoken — survives contact with payers. That, not the FDA, is the next catalyst.